The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.
 
Jie Wang
No Relationships to Disclose
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; Menarini; Pfizer; PrIME Oncology; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca; BMS; Hansoh; HenRui; Hutchison MediPharma; Roche
 
Xinmin Yu
No Relationships to Disclose
 
Yanping Hu
No Relationships to Disclose
 
Yuping Sun
No Relationships to Disclose
 
Zhijie Wang
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Chunhong Hu
Speakers' Bureau - AstraZeneca
 
Kunyu Yang
No Relationships to Disclose
 
Guosheng Feng
No Relationships to Disclose
 
Kejing Ying
No Relationships to Disclose
 
Wu Zhuang
No Relationships to Disclose
 
Jianying Zhou
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Jingxun Wu
No Relationships to Disclose
 
Shiang Jiin Leaw
No Relationships to Disclose
 
Jing Zhang
No Relationships to Disclose
 
Xiao Lin
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Nong Yang
No Relationships to Disclose